Cuproptosis-Related Gene – SLC31A1, FDX1 and ATP7B – Polymorphisms are Associated with Risk of Lung Cancer

Yun, Yuhui; Wang, Yun; Yang, Ende; Jing, Xin

doi:10.2147/pgpm.s372824

Cited by 28 publications

(29 citation statements)

References 44 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with genomic instability of FDX1 had the disposition to poor survival in cancer patients. There has been a research on single-nucleotide polymorphisms (SNPs) in cuproptosis-related genes demonstrating that FDX1-rs10488764 was associated with an increased risk of lung cancer ( Yun et al, 2022 ). Further study is needed to explore the effect of FDX1 in different tumors.…”

Section: Discussionmentioning

confidence: 99%

Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer

Dai

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Cuproptosis is a recently discovered form of programmed cell death. Ferredoxin 1 (FDX1) is a key gene that mediates this process. However, the role of FDX1 in human tumors is not clear.Methods: We comprehensively analyzed the differential expression and genetic alterations of FDX1 using multiomics data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database. Subsequently, we explored the association between FDX1 and tumor parameters such as genomic instability, RNA methylation modifications, immune infiltration and pathway activity. In addition, we performed functional enrichment analysis and assessed the sensitivity potential of FDX1-related drugs. Finally, we experimentally verified the functional effects of FDX1.Results: The analysis revealed differential expression of FDX1 in a variety of tumors. By analyzing the association of FDX1 expression with genomic instability, immune cell infiltration, signaling pathway etc. We explored the role of FDX1 in regulating cell activity. Also, we evaluated the function of FDX1 in biologic process and drug sensitivity. Our experimental results demonstrated that FDX1 exerts its antitumor effects through cuproptosis in liver hepatocellular carcinoma and non-small cell lung cancer cell lines.Conclusion: Our study reveals the functional effects of FDX1 in tumors and deepens the understanding of the effects of FDX1. We validated the inhibitory effect of FDX1 in copper induced cell-death, confirming the role of FDX1 as a cuproptosis biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer

Dai

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…A recent study performed by Tsvetkov et al reported that excess copper contributes to the aggregation of lipoylated dihydrolipoamide S-acetyltransferase intracellularly, leading to a novel of mitochondrial cell death called "cuproptosis" (8,17). Increasing lines of evidence had constructed a cuproptosis-related signature for the prognosis and immune response of certain types of cancer (32)(33)(34).…”

Section: Discussionmentioning

confidence: 99%

A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundBladder cancer (BLCA) is one of the deadliest diseases, with over 550,000 new cases and 170,000 deaths globally every year. Cuproptosis is a copper-triggered programmed cell death and is associated with the prognosis and immune response of various cancers. Long non-coding RNA (lncRNA) could serve as a prognostic biomarker and is involved in the progression of BLCA.MethodsThe gene expression profile of cuproptosis-related lncRNAs was analyzed by using data from The Cancer Genome Atlas. Cox regression analysis and least absolute shrinkage and selection operator analysis were performed to construct a cuproptosis-related lncRNA prognostic signature. The predictive performance of this signature was verified by ROC curves and a nomogram. We also explored the difference in immune-related activity, tumor mutation burden (TMB), tumor immune dysfunction and exclusion (TIDE), and drug sensitivity between the high- and low-risk groups.ResultsWe successfully constructed a cuproptosis-related lncRNA prognostic signature for BLCA including eight lncRNAs (RNF139-AS1, LINC00996, NR2F2-AS1, AL590428.1, SEC24B-AS1, AC006566.1, UBE2Q1-AS1, and AL021978.1). Multivariate Cox analysis suggested that age, clinical stage, and risk score were the independent risk factors for predicting prognosis of BLCA. Further analysis revealed that this signature not only had higher diagnostic efficiency compared to other clinical features but also had a good performance in predicting the 1-year, 3-year, and 5-year overall survival rate in BLCA. Notably, BLCA patients with a low risk score seemed to be associated with an inflamed tumor immune microenvironment and had a higher TMB level than those with a high risk score. In addition, patients with a high risk score had a higher TIDE score and a higher half maximal inhibitory concentration value of many therapeutic drugs than those with a low risk score.ConclusionWe identified a novel cuproptosis-related lncRNA signature that could predict the prognosis and immune landscape of BLCA.

show abstract

“…Lung cancer risk was shown to be elevated by the minor alleles of SLC31A1-rs10981694 and FDX1-rs10488764. In contrast, a lower incidence of the condition was associated with the minor alleles of rs9535826 and rs9535828 in ATP7B [37]. By using and analyzing a public database, some researchers investigated the relationship between cuproptosis-related genes and the prognosis of melanoma.…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer

Chen

Guan

et al. 2022

Discov Onc

View full text Add to dashboard Cite

Purpose Bladder cancer (BCa) is one of the most common malignant tumors in the urogenital system, characterized by the high recurrence rate, mortality rate and poor prognosis. Based on cuproptosis-related long noncoding RNAs (CRLs), this study set out to create a prediction signature to evaluate the prognosis of patients with BCa. Methods RNA-seq data including CRLs and related clinicopathological data were gathered from The Cancer Genome Atlas (TCGA) database (n = 428). The predictive signature was constructed after correlation analysis. Subsequently, relying on the analyzed data from the TCGA database and our sample collection, we examined and verified the connections between CRLs model and important indexes included prognosis, route and functional enrichment, tumor immune evasion, tumor mutation, and treatment sensitivity. Results Patients in the high-risk group had lower overall survival (OS) than that of low-risk group. Compared with clinicopathological variables, CRLs features have better predictive value according to receiver operating characteristic (ROC) curve. The expression level of CRLs was highly associated with the tumor progress, tumor microenvironment and tumor immune escape. Additionally, we identified that the mutation of TP53, TTN, KMT2D and MUC16 gene were founded in patients with BCa. Lapatinib, pazopanib, saracatinib, gemcitabine, paclitaxel and palenolactone had good antitumor effects for BCa patients in the high-risk group (all P < 0.001). Conclusion This study revealed the effects of CRLs on BCa and further established CRLs model, which can be used in clinic for predicting prognosis, immunological response and treatment sensitivity inpatient with BCa.

show abstract

Cuproptosis-Related Gene – SLC31A1, FDX1 and ATP7B – Polymorphisms are Associated with Risk of Lung Cancer

Cited by 28 publications

References 44 publications

Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer

Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer

A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer

Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer

Contact Info

Product

Resources

About